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In the last decade, technological advances and scientific 
knowledge about breast cancer have had a huge impact 
on all the subspecialties that make up the breast centers. 
In particular, Radiology has established itself  as a central 
element in the multidisciplinary approach to breast pathology, 
intervening in all stages of  breast cancer, including screening, 
diagnosis, staging and post-treatment follow-up.
This performance of  Mammary Radiology was well reflected 
in the recent SPRMN conferences, dedicated to breast 
centers.
Using criteria for breast cancer mammographic screening 
based only on sex and age, as it has been so far the case, 
seems scarce in the light of  current knowledge. It is 
important to identify high-risk groups that require different 
screening as well as factors that may increase cancer risk 
and decrease screening sensitivity, such as breast density. 
If  for the high-risk groups of  breast carcinoma, which 
include women with a heavy family history, a proven genetic 
mutation, or a history of  treatment in the childhood with 
radiotherapy due to Hodgkin's lymphoma, there is consensus 
about the type of  screening that should be done – annual 
breast MRI around the age of  25 - the same does not occur 
in the groups with high breast density (BI-RADS ACR-c and 
d), who represent about 40% of  women at a traceable age. 
There is no established consensus as to the most appropriate 
complementary method to be used in the referred breast 
density patterns, namely ultrasound, MRI or tomosynthesis. 
Of  these alternatives, since ultrasound is a labor-intensive 
and time-consuming examination and MRI is difficult to 
perform in such a large number of  women, the advantage 
lies in tomosynthesis, which represents a recent advance in 
digital mammography, allowing the breast to be "sliced" in 
planes which are 1 mm thick.
Tomosynthesis allowed the elimination of  false positives 
resulting from the overlapping of  breast tissue and reduce 
false negatives by increasing the rate of  detection of  breast 
cancer in all mammary patterns, especially in the most 
heterogeneous and dense. The impact of  tomosynthesis 
was so significant that its implementation was much faster 
than that of  direct digital mammography. Its approval by the 
Food and Drug Administration (FDA) occurred in 2011 and 
today no one thinks of  acquiring mammography equipment 
without tomosynthesis. There are several population 
screening programs under way with this technique, 
demonstrating exceptional results that reflect the significant 
increase in detection rate, as well as the reduction of  false 
positives and consequently the reduction of  the gauging rate. 
On the other hand, the technological advance that allowed a 
synthesized 2D image from tomosynthesis, identical to the 
image of  conventional mammography, with the same quality 
and without increasing radiation, also allowed an important 
dose reduction per examination. The synthesized 2D image 
constituted, therefore, a crucial stage in the process of  
tomosynthesis implementation.
MR is another indispensable modality in breast centers! In 
addition to its application in screening high-risk groups for 
breast cancer, the increased implementation in diagnostic 
settings has revealed high sensitivity and specificity, reflected 
in the amount of  information provided when rigorous 
technical acquisition results in high quality examination.
One of  the indications for breast MRI that has shown 
increasing adherence is the newly diagnosed breast cancer 
staging. Despite the discussion surrounding the topic, 
MRI has become a method that plays a pivotal role in 
surgical planning. The increased accuracy of  MRI in the 
assessment of  tumor extension and in the identification of  
in situ carcinoma component (CDIS) associated without 
mammographic translation, even in adipose patterns, has 
contributed to this performance. In addition, the rate of  
detection of  multifocality and, to a lesser extent, bilaterality, 
as well as the evaluation of  the ganglion chains.
The knowledge of  the heterogeneity of  breast cancer has 
added further indications for breast MRI at staging, namely 
in the molecular subtypes that are most frequently associated 
with multifocality, such as Her2 positive and luminal B 
tumors.
The number of  situations with indication for neoadjuvant 
therapy has increased as a result of  the advances in medical 
oncology with new and different therapeutic options, such 
as new antibodies for Her2 positive tumors. It also increases 
the rate of  complete pathological responses obtained with 
neoadjuvant therapy, especially in triple negative, Her2 
positive tumors and in tumors with high proliferative indexes 
(Ki67).
Current medicine is increasingly individualized and therapy 
is planned in a multidisciplinary environment based on the 
complete knowledge of  the patient's characteristics and 
neoplasia. It is as important to know the molecular subtype 
of  the lesion as to know if  it is single or multiple, its extent 
and degree of  involvement of  the ganglion chains. Much of  
the information necessary for the complete picture of  the 
neoplasm is provided by imaging techniques: mammography 
and tomosynthesis, ultrasound, and, especially, breast MRI.
6Diagnosis of  breast lesions using percutaneous biopsy 
techniques, guided by imaging methods, has been the 
common practice since the early 1990s and there is currently 
no room for surgical biopsy. Any surgery should be preceded 
by percutaneous diagnosis, since these are techniques of  high 
precision and high concordance rate with the final histological 
diagnosis. This is why, in view of  microcalcifications 
suspected of  malignancy, it is mandatory that the biopsy 
be performed using a vacuum technique (BAV) in order to 
obtain a representative sample of  the lesion, with a lower risk 
of  disagreement with the final histology.
The advancement of  biopsy techniques, the increased 
user experience and the greater knowledge about lesions 
of  uncertain malignant potential or B3 lesions and their 
upgrading risk, have led to the increasing use of  BAV not 
only for diagnostic purposes but also therapeutic ones. The 
current recommendations in B3 lesions, such as flat epithelial 
atypia, classic lobular neoplasia, papillary lesions and in the 
radiological scar are for the excision of  these lesions by BAV 
and non-surgical, followed by imaging surveillance during 5 
years.
In cases in where BAV reveals the diagnosis of  CDIS, it 
is known that treatment may fail, with development of  
invasive carcinoma in 15 to 20% of  the cases, and on the 
other hand there is a large proportion of  treated patients 
that does not relapse during their life. These facts have 
reinforced the role of  breast MRI in pre-surgical assessment 
of  CDIS as a more sensitive and adequate technique for the 
evaluation of  extension when compared to mammography, 
particularly in clinically significant tumors: major and of  high 
grade. They also raised the controversy of  overtreatment, 
motivating international clinical trials to identify criteria that 
determine the progression to higher-grade CDIS and/or 
invasive carcinoma and, potentially, provide models based 
on the evidence of  active surveillance as a future option of  
approach on low risk patients.
One area that is likely to change over the next few years is the 
follow-up after therapy. At present almost all international 
recommendations refer only to annual mammography. We 
know that there are subtypes that associate with a higher 
probability of  early relapse, that there are dense patterns and 
surgical procedures that make it difficult to detect early the 
relapse with mammography. It is already possible to identify 
groups where the risk of  relapse is greater and the follow-up 
should include MRI.
From the systemic point of  view, the increasing importance 
attributed to the diagnosis of  oligometastatic disease, due 
to the existing therapeutic options and with an apparent 
impact on survival, will also lead to a change in surveillance 
recommendations for the early detection of  recurrence at a 
distance.
The challenges that Mammary Radiology poses to Medical 
Radiologists require dedication and knowledge that extend 
beyond the scope of  Radiology. The scientific quality of  the 
recent Conference, resulting from the sub-specialization of  
the participants and their integration in a multidisciplinary 
environment, was aimed at motivating and alerting the 
audience to the need and importance of  the sub-specialization 
in Mammary Radiology.
